Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 16.62
PRAN's Cash to Debt is ranked higher than
71% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. PRAN: 16.62 )
PRAN' s 10-Year Cash to Debt Range
Min: 16.62   Max: No Debt
Current: 16.62

Equity to Asset 0.82
PRAN's Equity to Asset is ranked higher than
84% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PRAN: 0.82 )
PRAN' s 10-Year Equity to Asset Range
Min: 0.73   Max: 0.99
Current: 0.82

0.73
0.99
F-Score: 2
Z-Score: 7.84
M-Score: -1.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -168.18
PRAN's Operating margin (%) is ranked higher than
64% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. PRAN: -168.18 )
PRAN' s 10-Year Operating margin (%) Range
Min: -3850.92   Max: -168.18
Current: -168.18

-3850.92
-168.18
Net-margin (%) -167.86
PRAN's Net-margin (%) is ranked higher than
64% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. PRAN: -167.86 )
PRAN' s 10-Year Net-margin (%) Range
Min: -3945.4   Max: -167.86
Current: -167.86

-3945.4
-167.86
ROE (%) -55.72
PRAN's ROE (%) is ranked higher than
60% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. PRAN: -55.72 )
PRAN' s 10-Year ROE (%) Range
Min: -200.61   Max: -6.4
Current: -55.72

-200.61
-6.4
ROA (%) -45.61
PRAN's ROA (%) is ranked higher than
61% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. PRAN: -45.61 )
PRAN' s 10-Year ROA (%) Range
Min: -163.65   Max: -0.5
Current: -45.61

-163.65
-0.5
ROC (Joel Greenblatt) (%) -562.51
PRAN's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. PRAN: -562.51 )
PRAN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -22895.83   Max: -562.51
Current: -562.51

-22895.83
-562.51
» PRAN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

PRAN Guru Trades in Q4 2012

Jim Simons 26,500 sh (-37.2%)
» More
Q1 2013

PRAN Guru Trades in Q1 2013

Jim Simons Sold Out
» More
Q3 2013

PRAN Guru Trades in Q3 2013

Jim Simons 163,200 sh (New)
» More
Q4 2013

PRAN Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PRAN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.30
PRAN's P/B is ranked higher than
57% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PRAN: 5.30 )
PRAN' s 10-Year P/B Range
Min: 0.44   Max: 31.63
Current: 5.3

0.44
31.63
P/S 19.30
PRAN's P/S is ranked lower than
54% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. PRAN: 19.30 )
PRAN' s 10-Year P/S Range
Min: 4.83   Max: 126.5
Current: 19.3

4.83
126.5
EV-to-EBIT 10.80
PRAN's EV-to-EBIT is ranked higher than
78% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. PRAN: 10.80 )
PRAN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 10.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.60
PRAN's Price/Net Cash is ranked higher than
75% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. PRAN: 7.60 )
PRAN' s 10-Year Price/Net Cash Range
Min: 1.03   Max: 43
Current: 7.6

1.03
43
Price/Net Current Asset Value 6.10
PRAN's Price/Net Current Asset Value is ranked higher than
80% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. PRAN: 6.10 )
PRAN' s 10-Year Price/Net Current Asset Value Range
Min: 1.03   Max: 43
Current: 6.1

1.03
43
Price/Tangible Book 5.60
PRAN's Price/Tangible Book is ranked higher than
74% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. PRAN: 5.60 )
PRAN' s 10-Year Price/Tangible Book Range
Min: 0.63   Max: 43
Current: 5.6

0.63
43
Price/Median PS Value 0.70
PRAN's Price/Median PS Value is ranked higher than
88% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PRAN: 0.70 )
PRAN' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 10.24
Current: 0.7

0.69
10.24
Forward Rate of Return (Yacktman) -22.11
PRAN's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. PRAN: -22.11 )
PRAN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1263.4   Max: 1708.7
Current: -22.11

-1263.4
1708.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PBT.Australia, PBN.Germany, PBNA.Germany
Prana Biotechnology Ltd. was incorporated under the laws of the Commonwealth of Australia on November 11, 1997. The company is an Australian biotechnology company, which is at an early stage in the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for it's MPAC (Metal-Protein Attenuating Compound) technology include Alzheimer's, Parkinson's and Huntington's diseases and brain cancer.
» More Articles for NAS:PRAN

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide